“…it is important to note that this is the first [Good Clinical Practice] pediatric epinephrine study conducted for the purpose of regulatory approval,” wrote investigators, led by David M. Fleischer, from Children's Hospital Colorado, University of Colorado School of Medicine. “The comparison of pediatric data with comparable data in adults provides the necessary scientific rationale to conclude that pediatric doses of neffy have a comparable [pharmacokinetic] profile relative to epinephrine injection.”